CN101817877B - Anti-opioid peptide active fragment - Google Patents
Anti-opioid peptide active fragment Download PDFInfo
- Publication number
- CN101817877B CN101817877B CN2010101226191A CN201010122619A CN101817877B CN 101817877 B CN101817877 B CN 101817877B CN 2010101226191 A CN2010101226191 A CN 2010101226191A CN 201010122619 A CN201010122619 A CN 201010122619A CN 101817877 B CN101817877 B CN 101817877B
- Authority
- CN
- China
- Prior art keywords
- morphine
- seq
- opioid
- peptide
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 20
- 239000003399 opiate peptide Substances 0.000 title abstract description 5
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 230000014509 gene expression Effects 0.000 claims description 7
- 241000894006 Bacteria Species 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 232
- 229960005181 morphine Drugs 0.000 abstract description 115
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 73
- 230000003502 anti-nociceptive effect Effects 0.000 abstract description 48
- 239000003814 drug Substances 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 31
- 230000036592 analgesia Effects 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 13
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 13
- 230000003042 antagnostic effect Effects 0.000 abstract description 9
- 229920001184 polypeptide Polymers 0.000 abstract description 8
- 238000002360 preparation method Methods 0.000 abstract description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000003313 weakening effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 108
- 230000008485 antagonism Effects 0.000 description 58
- 238000002347 injection Methods 0.000 description 31
- 239000007924 injection Substances 0.000 description 31
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 241000282898 Sus scrofa Species 0.000 description 25
- 210000004556 brain Anatomy 0.000 description 24
- 238000000034 method Methods 0.000 description 22
- 208000024891 symptom Diseases 0.000 description 22
- 239000000203 mixture Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 14
- 102100028489 Phosphatidylethanolamine-binding protein 1 Human genes 0.000 description 14
- 238000007912 intraperitoneal administration Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000001467 acupuncture Methods 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 101000987493 Homo sapiens Phosphatidylethanolamine-binding protein 1 Proteins 0.000 description 9
- 241000282894 Sus scrofa domesticus Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000003462 vein Anatomy 0.000 description 9
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 8
- 229960004127 naloxone Drugs 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 7
- 239000003112 inhibitor Substances 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 101100108551 Mus musculus Akr1b7 gene Proteins 0.000 description 6
- 239000000287 crude extract Substances 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 4
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 101800001941 Hippocampal cholinergic neurostimulating peptide Proteins 0.000 description 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 3
- 239000008896 Opium Substances 0.000 description 3
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 3
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 3
- 206010048010 Withdrawal syndrome Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005611 electricity Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 230000009191 jumping Effects 0.000 description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 3
- 229960001027 opium Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 2
- 101710204191 Phosphatidylethanolamine-binding protein 1 Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000124033 Salix Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- JCABVIFDXFFRMT-DIPNUNPCSA-N [(2r)-1-[ethoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] octadec-9-enoate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC)OC(=O)CCCCCCCC=CCCCCCCCC JCABVIFDXFFRMT-DIPNUNPCSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 201000006747 infectious mononucleosis Diseases 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003533 narcotic effect Effects 0.000 description 2
- 239000000236 nitric oxide synthase inhibitor Substances 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- CSYSULGPHGCBQD-UHFFFAOYSA-N s-ethylisothiouronium diethylphosphate Chemical compound CCSC(N)=N.CCOP(O)(=O)OCC CSYSULGPHGCBQD-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 102100035785 Acyl-CoA-binding protein Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000259759 Cassida nobilis Species 0.000 description 1
- 108010039287 Diazepam Binding Inhibitor Proteins 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220369445 c.668T>C Human genes 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000000442 meristematic effect Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 102000051624 phosphatidylethanolamine binding protein Human genes 0.000 description 1
- 108700021017 phosphatidylethanolamine binding protein Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 102000009929 raf Kinases Human genes 0.000 description 1
- 108010077182 raf Kinases Proteins 0.000 description 1
- 230000010656 regulation of insulin secretion Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 102220023257 rs387907546 Human genes 0.000 description 1
- 102220023256 rs387907547 Human genes 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an anti-opioid peptide, an antagonistic peptide thereof and application thereof. The anti-opioid peptide is one of the following amino acid residue sequences: 1) SEQ ID NO: 1; 2) SEQ ID NO: 3-5; 3) and (3) converting SEQ ID NO: 1; SEQ ID NO: 3-5 by substituting, deleting or adding one to ten amino acid residues of the sequence, and has antagonistic morphine antinociceptive effect. The antagonistic peptide is one of the following amino acid residue sequences: 1) SEQ ID NO: 9-11; 2) and (3) mixing the amino acid sequence shown in SEQ ID NO: 9-11, by substituting, deleting or adding one to ten amino acid residues, the polypeptide has the effects of enhancing morphine analgesia, reversing morphine tolerance and/or weakening or eliminating withdrawal symptoms. The anti-opioid peptide, the active fragment thereof and the antagonistic peptide play important roles in the fields of medicine and preparation of drug-relief medicines, and have wide application prospects.
Description
The application is that application number is 200710118104.2, the applying date is to divide an application for " application of a kind of anti-opioid and antagonism peptide thereof and this antagonism peptide " on 06 28th, 2007, invention and created name.
Technical field
The present invention relates to peptide section and encoding gene thereof and application, particularly relate to a kind of anti-opioid and antagonism peptide thereof, have in preparation with this antagonism peptide and strengthen morphine analgesia, reverse the morphine tolerance and/or weaken or eliminate application in the medicine of Withrawal symptom effect with antagonism morphine antinociceptic effect.
Background technology
As everyone knows, worldwide Chang Jue drug trafficking and addiction activity has become a malignant tumor of harm society, has seriously disturbed orderly economic construction and social stability, and in addition, intravenous drug has also caused the soaring of acquired immune deficiency syndrome (AIDS) crowd's infection rate.At present, though all strengthening, national governments unite the dynamics of combatting drug trafficking, but take drugs, narco-trafficking still remains incessant after repeated prohibition, one of them important reasons is exactly that morphine tolerance and the principle that relies on really or are not fully illustrated as yet, does not still have effective drug rehabilitation means in the world.External employing at first " alternative medicine " be that the medicine with methadone one class replaces opium in withdrawal, this therapy will cause tolerance and the dependence of patient to methadone class medicine.At home, Mr. Yang Guodong of Ningbo narcotic house adopts hyoscine to cooperate the other medicines drug rehabilitation, does not also separate resolution addiction problem fully.Professor Han Jisheng adopts acupuncture and moxibustion therapeutic apparatus treatment Withrawal symptom, that attempts that electric pulse stimulation by CF improves endogenous opiate in the body synthesizes to come mitigation symptoms, but its greatest drawback be the efficient limited of acupuncture analgesia among the crowd and also constantly acupuncture also have the tolerance problem.Recently, Shijiazhuang Chinese materia medica expert Wang Yan debates disease executing to the opium Withrawal symptom and controls, and adopts " tortoise beetle ball " treatment withdrawal syndrome, through clinical further check and perfect.Therefore, press for a kind of can and the dependence from thorough elimination morphine tolerance on the source, and the anti-additive medicament that weakens or eliminate Withrawal symptom.
The albumen of known PEBP family extensively is present in yeast, nematode, fruit bat and each kind of plant and mammiferous Different Organs in nature, they have conservative property, do not have homology with the proteic sequence of other known structure or function.The proteic biological function of PEBP is very various, and the signal that it is grown to bloom signal and meristematic tissue plant plays regulating effect.Mammal, PEBP albumen can make it not to be activated by the phosphorylation that Raf-1 suppresses MEK, so the title of Raf kinase inhibition albumen (RKIP) is arranged again, it regulates one group of signal of Raf/MEK/ERK, relevant with the mitotic division of cell with differentiation, relate to the transfer of tumour cell.In central nervous system, PEBP albumen not only stimulates predecessor's albumen of cholinergic nerve peptide (HCNP) as hippocampus, and as ATP, opium and phosphatidyl ethanol ammonia conjugated protein.People (Ojika K. such as Ojika K., Mitake S., Tohdoh N., Appel S.H., Otsuka Y., Katada E.And Matsukawa N. (2000) Hippocampal cholinergic neurostimulating peptides (HCNP) .Prog.Neurobiol.60,37-83.Iwase T, Ojika K, Matsukewa N, et al. Muscarinic cholinergic and glutamatergic reciprocal regulation of expressionof hippocampal choline
Summary of the invention
The purpose of this invention is to provide a kind of anti-opioid with antagonism morphine antinociceptic effect.
Anti-opioid provided by the present invention, called after 21Kd is one of following amino acid residue sequences:
1) the SEQ ID NO:1 in the sequence table;
2), has the polypeptide of antagonism morphine antinociceptic effect with replacement, disappearance or the interpolation of the amino acid residue sequence of SEQ ID NO:1 in the sequence table through one to ten amino-acid residue.
One to ten amino-acid residue of described replacement, disappearance or interpolation can be the amino-acid residue in the non-structural domain, and its change can not exert an influence to this proteic function, for example, and increase histidine-tagged etc.
SEQ ID NO:1 in the sequence table is made up of 186 amino-acid residues.
The gene of code book invention anti-opioid 21Kd is one of following nucleotide sequence:
1) dna sequence dna of SEQ ID NO:2 in the sequence table;
2) dna sequence dna of SEQ ID NO:1 in the code sequence tabulation;
3) with sequence table in the nucleotide sequence of the nucleotide sequence that limits of SEQ ID NO:2 with 90% above homology;
4) nucleotide sequence of the dna sequence dna hybridization that under the rigorous condition of height, can limit with the SEQ ID NO:2 in the sequence table.
The rigorous condition of described height is: (or 0.1 * SSC), the solution of 0.1%SDS is hybridized under 65 ℃ and is washed film with 0.1 * SSPE.
SEQ ID NO:2 in the sequence table is by 558 based compositions, and coding has the protein of the amino acid residue sequence of SEQ ID NO:1 in the sequence table.
Test shows that above-mentioned anti-opioid 21Kd has a series of active fragments, and they can be one of following amino acid residue sequences:
1) the SEQ ID NO:3 in the sequence table;
2) the SEQ ID NO:4 in the sequence table;
3) the SEQ ID NO:5 in the sequence table;
4), and has the polypeptide of antagonism morphine antinociceptic effect with replacement, disappearance or the interpolation of the amino acid residue sequence of SEQ ID NO:3-5 in the sequence table through one to ten amino-acid residue.
One to ten amino-acid residue of described replacement, disappearance or interpolation can be the amino-acid residue in the non-structural domain, and its change can not exert an influence to this proteic function.
SEQ ID NO:3 in the sequence table is made up of 13 amino-acid residues, with its called after 21Kd-13; SEQ ID NO:4 in the sequence table is made up of 14 amino-acid residues, with its called after 21Kd-14; SEQID NO:5 in the sequence table is made up of 21 amino-acid residues, with its called after 21Kd-21.
The nucleotide sequence that encode the gene of above-mentioned anti-opioid active fragments, has the nucleotide sequence of 90% above homology with this gene or can hybridize with the dna sequence dna of its qualification under the rigorous condition of height also is subjected to protection of the present invention.
The rigorous condition of described height is: (or 0.1 * SSC), the solution of 0.1%SDS is hybridized under 65 ℃ and is washed film with 0.1 * SSPE.
SEQ ID NO:6 in the sequence table is by 39 based compositions, the anti-opioid 21Kd active fragments shown in the coding SEQ ID NO:3; SEQ ID NO:7 in the sequence table is by 42 based compositions, the anti-opioid 21Kd active fragments shown in the coding SEQ ID NO:4; SEQ ID NO:8 in the sequence table is by 63 based compositions, the anti-opioid 21Kd active fragments shown in the coding SEQ ID NO:5.
The antagonism peptide of anti-opioid 21Kd of the present invention is one of following amino acid residue sequences:
1) the SEQ ID NO:9 in the sequence table;
2) the SEQ ID NO:10 in the sequence table;
3) the SEQ ID NO:11 in the sequence table;
4) amino acid residue sequence of SEQ ID NO:9-11 in the sequence table is had through replacement, disappearance or the interpolation of one to ten amino-acid residue strengthen morphine analgesia, reverse the morphine tolerance and/or weaken or eliminate the polypeptide of Withrawal symptom effect.
One to ten amino-acid residue of described replacement, disappearance or interpolation can be the amino-acid residue in the non-structural domain, and its change can not exert an influence to this proteic function.
SEQ ID NO:9 in the sequence table is made up of 13 amino-acid residues, with its called after CP-21Kd-13; SEQ ID NO:10 in the sequence table is made up of 14 amino-acid residues, with its called after CP-21Kd-14; SEQ ID NO:11 in the sequence table is made up of 21 amino-acid residues, with its called after CP-21Kd-21.
The nucleotide sequence that encode the gene of above-mentioned anti-opioid 21Kd antagonism peptide, has the nucleotide sequence of 90% above homology with this gene or can hybridize with the dna sequence dna of its qualification under the rigorous condition of height also is subjected to protection of the present invention.
The rigorous condition of described height is: (or 0.1 * SSC), the solution of 0.1%SDS is hybridized under 65 ℃ and is washed film with 0.1 * SSPE.
SEQ ID NO:12 in the sequence table is by 39 based compositions, the antagonism peptide of the anti-opioid 21Kd shown in the coding SEQ ID NO:9; SEQ ID NO:13 in the sequence table is by 42 based compositions, the antagonism peptide of the anti-opioid 21Kd shown in the coding SEQ ID NO:10; SEQ ID NO:14 in the sequence table is by 63 based compositions, the antagonism peptide of the anti-opioid 21Kd shown in the coding SEQ ID NO:11.
Contain that arbitrary segmental primer also belongs to protection scope of the present invention in antagonism peptide expression carrier, transgenic cell line and the host bacterium of above-mentioned anti-opioid 21Kd and this gene that increases.
The antagonism peptide of above-mentioned anti-opioid 21Kd can adopt conventional artificial synthesis directly to obtain; method synthetic such as solid-phase synthesis as available fmoc protection; maybe can entrust the biotech firm of specialty synthetic (dodging the synthetic company limited of brilliant biological polypeptide etc.) as U.S.'s connection (Xi'an) bio tech ltd or Shanghai; in addition, the method that also can utilize microbial fermentation to express obtains.The method of the above-mentioned antagonism peptide of expression provided by the present invention is that the recombinant expression vector that will contain the antagonism peptide gene of above-mentioned anti-opioid 21Kd imports host cell, expresses the antagonism peptide that obtains anti-opioid 21Kd.
Described host can be intestinal bacteria, yeast, mammalian cell, insect cell or Bacillus subtilus etc., is preferably intestinal bacteria.
Described intestinal bacteria can be E.coli BL21 (DE3), E.coli DH5 α or E.coli Top10 etc.
Be used to make up the described carrier that sets out that contains the antagonism peptide expression carrier of anti-opioid 21Kd can be any one can be at the prokaryotic expression carrier of expression in escherichia coli foreign gene, as pET-22b, pET-11c, pET-30a, pET-28a, pET-28b or pET-28c etc.
Wherein, be the carrier that sets out with pET-22b, the antagonism peptide expression carrier that contains anti-opioid 21Kd of structure is pET-CP-21Kd-8+5, pET-CP-21Kd-13, pET-CP-21Kd-14 or pET-CP-21Kd-21.
Above-mentioned recombinant expression vector all can make up according to ordinary method.
The method that above-mentioned recombinant expression vector is transformed the host bacterium can be method for transformation commonly used in the bioengineering field, as the protoplast transformation method of heat shock method, electrotransformation, joint conversion method or PEG mediation etc.
Cultivation contains the substratum and the culture condition of host cell of the antagonism peptide gene of anti-opioid 21Kd, all can be substratum and the culture condition of cultivating the host that sets out.Wherein, need add inductor when cultivating described recombination bacillus coli host, as IPTG etc., add IPTG concentration can be 0.1-1.0mmol/L, be preferably 0.2mmol/L, inducing temperature can be 16-37 ℃, be preferably 30 ℃, induction time can be 2-4 hour, is preferably 3 hours.
The antagonism peptide of described anti-opioid 21Kd strengthens morphine analgesia in preparation, reverse the morphine tolerance and/or weaken or the application eliminated in the medicine of Withrawal symptom effect also is that the present invention will protect.Certainly, be the medicine of activeconstituents with the antagonism peptide of described anti-opioid 21Kd, the content that needs protection of the present invention especially, this medicine has and strengthens morphine analgesia, reverses the morphine tolerance and/or weaken or eliminate the effect of Withrawal symptom.
Antagonism peptide with anti-opioid 21Kd is in the medicine of activeconstituents, and its activeconstituents can be selected from one or several in the following amino acid residue sequence:
1) the SEQ ID NO:9 in the sequence table;
2) the SEQ ID NO:10 in the sequence table;
3) the SEQ ID NO:11 in the sequence table;
4) amino acid residue sequence of SEQ ID NO:9-11 in the sequence table is had through replacement, disappearance or the interpolation of one to ten amino-acid residue strengthen morphine analgesia, reverse the morphine tolerance and/or weaken or eliminate the polypeptide of Withrawal symptom effect.
When needing, can also add one or more acceptable accessories in said medicine, described auxiliary material comprises thinner, vehicle, weighting agent, tackiness agent, wetting agent, absorption enhancer, tensio-active agent, lubricant and the stablizer etc. of pharmaceutical field routine.
Medicine of the present invention can be made various ways such as injection liquid, dry powder injection, tablet or granula.The medicine of above-mentioned various formulations all can be according to the ordinary method preparation of pharmaceutical field.
Adult's consumption of said medicine be generally the 0.01-0.5mg/kg body weight/time, can one or many use, be generally the course of treatment 10 to 20 days.
The invention provides a kind of separation and purification goes out from the pig brain anti-opioid 21Kd and active fragments thereof, it has antagonism morphine antinociceptic effect.The increase that the drug abuse process is accompanied by drugs dosage can impel this proteic synthetic increase, the formation that causes the morphine tolerance and rely on.The present invention utilizes and has interactional principle between the protein molecule, according to the sequence of its three active fragmentss, and the antagonism peptide of this anti-opioid 21Kd that has designed.Experimental results show that, the antagonism peptide of synthetic can be used as the inhibitor of endogenous anti-opioid, antagonism peptide by three active fragmentss of intravenous injection, can improve the effect of morphine antinociceptic effect, reduce the morphine consumption, in addition, the molecular weight of these antagonism peptides is less than 2000 dalton, be easier to pass through hemato encephalic barrier, region of interest in central nervous system plays the effect of offsetting endogenous anti-opioid effect, thereby it can be prepared into the medicine that strengthens morphine analgesia, reverses the morphine tolerance and/or weaken or eliminate the Withrawal symptom effect as activeconstituents.This medicine has the following advantages: 1) evident in efficacy: activeconstituents antagonism peptide is to reach the purpose that strengthens morphine analgesia, the tolerance of reverse morphine and eliminate or weaken drug addict's Withrawal symptom by eliminating endogenous anti-opioid unnecessary in drug addict's body and effect thereof, can eliminate Withrawal symptom from the source; 2) the antagonism peptide of Huo Deing all is that some amino-acid residue quantity are no more than 25 small peptide, and is synthetic easily, is convenient to development research; 3) these small peptides enter in the body and are degraded easily, do not possess the side effect that produces antibody, and are safe; 4) medication is convenient, can be by multiple mode administrations such as intravenous injection mode or sublingual lozenges, to eliminate or to weaken the symptom of morphine abstinence syndrome; 5) this small peptide is stable, the preparation method is simple and easy to do, can be applicable to large-scale industrial production, and low production cost, can alleviate patient's economical load.Anti-opioid 21Kd of the present invention and active fragments thereof and its antagonism peptide will play a significant role in the preparation field of medical science and anti-additive medicament, have a extensive future.
Below in conjunction with specific embodiment the present invention is described in further details.
Description of drawings
Fig. 1 causes the detected result of mouse vas deferens effect of contraction to electricimpulse for Pedis Canitis extract
Fig. 2 injects the detected result of dog brain crude extract to rat acupuncture analgesia effects in the tricorn
Fig. 3 A and Fig. 3 B are the detected result of anti-opioid 21Kd to the antagonistic effect of morphine antinociceptic effect
Fig. 4 A-Fig. 4 C is the active peptide segment 21Kd-21 of anti-opioid 21Kd, and 21Kd-14 and 21Kd-13 are to the detected result of morphine antinociceptic effect influence
Fig. 5 is the detected result of ScFv to the influence of morphine antinociceptic effect
Fig. 6 injects the detected result of the ScFv of various dose to the influence of challenge dose morphine (50mg/kgi.p.) antinociceptic effect in morphine tolerance mouse tricorn
Fig. 7 is the detected result of nmda receptor and the influence of NOS in anti-opioid 21Kd and active fragments antagonism morphine antinociceptic effect thereof
Fig. 8 A-Fig. 8 C is CP-21Kd-21, and CP-21Kd-14 and CP-21Kd-13 are to the detected result of morphine antinociceptic effect influence
Embodiment
Method therefor is ordinary method if no special instructions among the following embodiment, concrete steps can referring to: " Molecular Cloning:A Laboratory Manual〉(Sambrook, J., Russell, DavidW., Molecular Cloning:A Laboratory Manual, 3
RdEdition, 2001, NY, Cold SpringHarbor).
The primer and dna sequence dna are given birth to worker's biotechnology company limited by Shanghai and are synthesized.
Used experiment mice is the Kunming male mice (available from Institute of Zoology, Academia Sinica) with age in 8-10 week, body weight 20-22g among the following embodiment
The acquisition and the functional verification of embodiment 1, anti-opioid 21Kd and active fragments thereof
One, the acquisition of pig brain anti-opioid 21Kd
1, the discovery of anti-opioid
The mouse vas deferens sample that is exsomatizing, (the 0.1MS ripple is wide to give square-wave pulse, 1 time/second) stimulate and can cause contraction (concrete grammar is referring to document: J.Hughes et al (1975) Effect of morphine on adrenergictransmission in the Mouse Vas deferens.Assessment of agonist and antagonistpotencies of Narcotic analgesics 53,371-381), then, successively in perfusate, add Srm-Rhotaard (3.2nM) or Pedis Canitis extract (AOS, 200 μ g/mL) (for the dog brain extracts concentrated solution earlier after Sephadex G-50 gel (available from pharmacia company) filtration, (CM-C is available from H.Reeve-Angel﹠amp for carboxymethyl-Mierocrystalline cellulose; .Co.Ltd behind the cation-exchange chromatography, obtain sample company)), observe the influence that the electricity irritation mouse vas deferens is caused shrinking effect.(M represents to morphine as shown in Figure 1, MAP represents to Pedis Canitis extract), experiment is found in dog brain crude extract, exist and to strengthen the composition that the electricity irritation mouse vas deferens shrinks, and the effect that the enhancing shrinking effect of this sample and morphine inhibition electricity irritation mouse vas deferens shrink is on the contrary, therefore, after in this dog brain crude extract injection mouse tricorn, the antinociceptic effect that can be observed morphine is suppressed significantly.
In addition, above-mentioned dog brain crude extract is injected the tricorn (400 μ g/20 μ l/ only) of the effective rat of acupuncture analgesia (6), is contrast (6) with physiological saline (Saline), and the beginning acusector is induced stimulation after 10 minutes, the shout reaction of rat to noxious stimulus observed at every interval ten minutes.(I.C.V. represents by burying the conduit micro-injection sample in tricorn in advance the result, and on behalf of acusector, EA induce acupuncture analgesia as shown in Figure 2; X-coordinate is the dog brain crude extract injection back time, and ordinate zou is the variation of vocalization threshold), (Saline) is contrast with physiological saline, after acupuncture induction, the acupuncture analgesia effect appears in rat; After the injection of dog brain crude extract, carry out acupuncture induction again, the acupuncture analgesia effect of rat then disappears, and the AOS that exists in the above-mentioned experimental result prompting brain may be the infull internal factor of needle anaesthesia analgesia.
2, the acquisition of pig brain anti-opioid 21Kd
The method of separation and purification anti-opioid-21Kd from the pig brain, be also to be improvement (the long people (1997) of grade of willow slightly equally with reference to the long people's of grade of willow method, the separation and purification of the anti-morphine analgesia peptide of pig brain and antiserum(antisera) thereof are to the preliminary study of morphine tolerance influence, Chinese biological The Chemicals 13 volumes 3 phase 322-326), concrete grammar is: the concentrated solution of Medulla sus domestica extract is first after the Sephadex-G50 gel-filtration, after S-sepharose Fast Flow ion exchange chromatography (S-sepharose Fast Flow chromatography column is available from Pharmacia company) separates, get the sample of the 4th elution peak, after FPLC monos positively charged ion (FPLC monos chromatography column is available from Pharmacia company) exchange, with micro-reversed-phase HPLC purifying, obtain purified anti-opioid material.Because 20 amino-acid residues of this albumen N-end and the pulsating amino acid residue sequence of partial hydrolysis, there is the homology of height with the ox brain.In 106 amino-acid residues having measured, only terminal the 5th, 95,103 residue of N-there are differences.Its molecular weight is 20932 dalton, (claim phosphatidyl ethanol ammonia conjugated protein PhosphatidylethanolamineBinding Protein again with the 21Kd albumen of ox brain, PEBP) molecular weight 20,847 dalton are suitable, so this albumen is called 21Kd (claiming PEBP or RKIP again).Therefore, above-mentioned pig brain 21Kd albumen may belong to the PEBP protein family.The anti-opioid that obtains is carried out complete sequence determination, sequencing result shows that this anti-opioid has the amino acid residue sequence of SEQ ID NO:1 in the sequence table, form by 186 amino-acid residues, its encoding gene has the nucleotide sequence of SEQ ID NO:2 in the sequence table, by 558 based compositions.
Two, pig brain anti-opioid 21Kd antagonism morphine antinociceptic effect detects
1, the intracerebroventricular injection approach detects pig brain anti-opioid 21Kd antagonism morphine antinociceptic effect
The 21Kd albumen of purifying was injected morphine (20mg/kg) after 10 minutes in the abdominal cavity, do injection in the mouse tricorn, injected dose is respectively 0.24nM, 0.48nM and 0.96nM, is contrast with the physiological saline (Saline) of equal volume, detects the antinociceptic effect of morphine then.The result is (X-coordinate is represented the time behind the injection of morphia, and ordinate zou is represented the variation (%) of vocalization threshold, and n is every group of mouse quantity, and i.p. represents abdominal injection, and i.c.v. represents injection in the tricorn) as shown in Figure 3A.21Kd albumen is to the no effect of basis pain reaction of mouse, but the antinociceptic effect to morphine (20mg/kg i.p.) has significant antagonistic effect, and be subjected to different concns 21Kd albumen (0.24nM, 0.48nM influence and 0.96nM), the anti-injury of morphine area under a curve is respectively 98.5 ± 9.5,67.7 ± 8.0 and 55.6 ± 6.6 (cm under the different injection concentrations of 21Kd albumen
2), and the area of control group is 134.3 ± 6.7 (cm
2), The results of analysis of variance show exist between experimental group and the control group significant significant difference (P＜0.05, P＜0.001 and P＜0.001, df=28).
2, the tail vein injection approach detects pig brain anti-opioid 21Kd antagonism morphine antinociceptic effect
At mouse peritoneal injection 20mg/kg morphine (M
20) after 10 minutes, in the mouse tricorn, inject the 21Kd albumen of purifying by the tail vein, injected dose is respectively 1mg/kg, 2mg/kg and 4mg/kg, is contrast with the physiological saline (Saline) of equal volume, detects the antinociceptic effect of morphine then.(X-coordinate is represented the time behind the injection of morphia to the result shown in Fig. 3 B, ordinate zou is represented the variation (%) of vocalization threshold, n is every group of mouse quantity, i.p. represent abdominal injection, i.v. represent the tail intravenous injection), the 21Kd albumen of tail intravenous injection different concns also has significant antagonistic effect to the antinociceptic effect of morphine (20mg/kg i.p.), and relevant with the proteic concentration of 21Kd.The anti-injury of morphine area under a curve is respectively 111.2 ± 8.5,61.7 ± 5.4 and 36.5 ± 6.1 (cm under the different injection concentrations of 21Kd albumen
2), with control group 128.0 ± 5.0 (cm
2) compare, there is significant significant difference (P＜0.1, P＜0.001 and P＜0.001).
Above-mentioned test-results proves that anti-opioid 21Kd of the present invention has significant antagonism morphine antinociceptic effect.
Three, the acquisition of anti-opioid 21Kd active fragments and active detection the thereof
1, the acquisition of anti-opioid 21Kd active fragments
Supposition confirms that by step 2 it is because of 21Kd albumen is degraded to less segment in blood to the antagonistic effect of morphine antinociceptic effect that the tail vein injection approach awards anti-opioid 21Kd, the result who works at maincenter by hemato encephalic barrier.For verifying above-mentioned supposition, reference (Zh.W.Chen etal (1988) Isolation andcharacterization of porcine diazepam-binding inhibitor, a polypeptide not onlyof cerebral occurrence but also common in intestinal tissues and with effectson regulation of insulin release Eur.J.Biochem 174,239-245), with 21Kd albumen with after the pancreatin degraded, obtain 21 peak samples through micro-HPLC separation, detect the antagonism morphine antinociceptic effect of wherein several main component samples with the method identical with step 2, the result obtains three compositions with antagonism morphine antinociceptic effect, measure its amino acid residue sequence, the peptide section called after 21Kd-13 that will have the amino acid residue sequence of SEQ ID NO:3 in the sequence table, form by 13 amino-acid residues, its encoding gene has the nucleotide sequence of SEQ ID NO:6 in the sequence table, by 39 based compositions; To have the peptide section called after 21Kd-14 of the amino acid residue sequence of SEQ ID NO:4 in the sequence table, and be made up of 14 amino-acid residues, its encoding gene has the nucleotide sequence of SEQ ID NO:7 in the sequence table, by 42 based compositions; To have the peptide section called after 21Kd-21 of the amino acid residue sequence of SEQ ID NO:5 in the sequence table, and be made up of 21 amino-acid residues, its encoding gene has the nucleotide sequence of SEQ IDNO:8 in the sequence table, by 63 based compositions.Because the amino acid residue sequence of these three peptide sections and the amino acid residue sequence of the corresponding peptide section of ox brain PEBP albumen are in full accord, therefore prove that 21Kd albumen of the present invention belongs to the PEBP protein family really.
2, anti-opioid 21Kd active peptide segment 21Kd-21, the activity of 21Kd-14 and 21Kd-13 detects
Dodge the synthetic synthetic 21Kd-21 of company limited of brilliant biological polypeptide, these three peptide sections of 21Kd-14 and 21Kd-13 by U.S.'s connection (Xi'an) bio tech ltd and Shanghai.Detect active peptide segment 21Kd-21 (1.0,2.0,4.0nM), the 21Kd-14 (0.64,3.2,6.4nM) of various dose and 21Kd-13 (5.7,11.4,22.7nM) to morphine (M20 with the method identical with step 2,20mg/kg i.P.) influence of antinociceptic effect is contrast with physiological saline (Saline).(X-coordinate is represented the time behind the injection of morphia to detected result shown in Fig. 4 A-Fig. 4 C, ordinate zou is represented the variation (%) of vocalization threshold, n represents respectively to organize experiment mice quantity, i.p. represent intraperitoneal injection, i.c.v. intracerebral ventricle injection is surveyed in expression), 21Kd-21, the dosage range of 21Kd-14 and 21Kd-13 antagonism morphine antinociceptic effect respectively is 1.0-2.0-4.0nM, 1.6-3.2-6.4nM and 5.7-11.4-22.7nM, and their antagonism morphine antinociceptic effects are all relevant with dosage
One, the acquisition and the Function detection thereof of the soluble single-chain variable region antibody fragment of anti-opioid 21Kd
Utilize display technique of bacteriophage, [construction process is referring to Sblattero D to use people prophage antibody library that Italian International School for Advanced Studies (SISSA) Daniele Sblattero and Andrew Bradbury etc. make up, Lou J L, Marzari R, et al.In vivo recombination as atool to generate molecular diversity in phage antibody libraries.Reviews inMolecular Biotechnology.2001,74:303～315], from phage antibody library, filter out molecular weight about 20, the soluble single-chain variable region antibody fragment of 000 daltonian anti-opioid 21Kd abbreviates ScFv as.Inject morphine (M in the abdominal cavity
10,10mg/kg) after 10 minutes, ScFv is injected separately in the tricorn of normal mouse, injected dose is 4.8 μ g/6 μ l, is contrast with the phosphoric acid buffer (PBS) of equal volume, detects the antinociceptic effect of morphine then.Detected result is (n is every group of mouse quantity, and i.p. represents intraperitoneal injection, and i.c.v. represents to survey intracerebral ventricle injection) as shown in Figure 5, injects ScFv in the tricorn antinociceptic effect of morphine (10mg/kg i.p.) is significantly strengthened.In 110 minutes, the anti-injury of experimental mice morphine area under a curve is 603.8 ± 38.4, is 2.5 times of control group (239.4 ± 16.1), has significant significant difference (P＜0.001, t=8.7407, t
0.001=4.140, df=14), this experimental result further proves and has the restraining effect of 21Kd albumen to the morphine antinociceptic effect in the normal mouse brain really.
Two, detect the relation of anti-opioid 21Kd and morphine tolerance
Choose 20 healthy mices, every day three times, the Srm-Rhotaard of subcutaneous injection ascending-dose, injected dose is incremented to 60mg/kg by 10mg/kg, continues 10 days formation morphine tolerance mouse.Then 20 morphine tolerance mouse are divided into the 21Kd-ScFv antibody group (5 every group) that morphine tolerates control group (not injecting 21Kd-ScFv) and injects three different concns.At the 11st day, inject the morphine (50mg/kg) of challenge dose earlier by the abdominal cavity, after 10 minutes, in tricorn, inject 4 μ g/6 μ l more respectively, the 21Kd-ScFv of 6 μ g/6 μ l and three kinds of dosage of 8 μ g/6 μ l, observe their morphine antinociceptic effect respectively, the healthy mice that tolerates with non-morphine is the blank group.(n is a mouse quantity to the result as shown in Figure 6, ordinate zou is a morphine antinociceptic effect area under a curve, X-coordinate is the different experiments group), at the control group that forms the morphine tolerance, challenge dose morphine antinociceptic effect area under a curve is 121.52 ± 21.2 (cm in 90 minutes
2), morphine (50mg/kgi.p.) the antinociceptic effect area under a curve of three dosage groups of 21Kd-ScFv (4.0 μ g/6 μ l, 6 μ g/6 μ l and 8 μ g/6 μ l) is respectively 170.18 ± 25.3,224.25 ± 49.6 and 269.97 ± 31.3 (cm
2).The 21Kd-ScFv of various dose has reversed the antinociceptic effect of challenge dose morphine to some extent, wherein, the reverse morphine antinociceptic effect of 21Kd-ScFv 6 μ g/6 μ l and 8 μ g/6 μ l dosage groups has statistical significance (* representative is compared p＜0.05 with the control group of tolerance; The * representative is compared p＜0.01 with the control group of tolerance).Blank group (261.65 ± 27cm with non-tolerance
2) compare, 21Kd-ScFv (8 μ g/6 μ l) group has reached the degree that reverses the morphine tolerance fully.Above-mentioned experimental result shows that in the forming process of morphine tolerance, the resultant quantity of endogenous anti-opioid 21Kd increases, and may be one of important factor that forms the morphine tolerance.
Three, detect the relation that anti-opioid 21Kd and morphine rely on
Choose 12 healthy mices, every day three times, the morphine of subcutaneous injection ascending-dose, injected dose is incremented to 80mg/kg by 10mg/kg, continues the tolerance of 12 days formation morphines and relies on mouse.Then 12 morphine tolerances and dependence mouse are divided into control group and experimental group.Wherein, control group is to inject the last time after the morphine during 6-8 hour, and abdominal injection opioid peptides antagonist Narlan (Naloxone) (available from Sigma company, 10mg/kg i.p.) is observed the number of times of Withrawal symptom-jump that mouse may bring out.Experimental group and control group are to match the observation that experimentizes fully, and operational difference only is that abdominal injection Naloxone (10mg/kg) is preceding, inject 21Kd-ScFv (8 μ g/10 μ l) through tricorn earlier.The result is as shown in table 1, and the number of times that jumping appears in control group mice is followed successively by 0,1,15,36,89,90; And the inferior number average that jumping appears in experimental mice disappears, but the amount of injecting 21Kd-ScFv antibody through tricorn does not wait, jump just disappears after having three tricorns of 1 need to inject 21Kd-ScFv, there are 2 after twice tricorn injects 21Kd-ScFv, to jump and disappear, just no longer occur jumping after having 3 only once to inject 21Kd-ScFv.Above-mentioned experimental result explanation, every day three times, there is bigger individual difference in the mouse that continues tolerance of 12 days formation morphines and dependence with ascending-dose subcutaneous injection morphine, the number of times of the jump that Naloxone brought out can reach 0-90 time, and tricorn injection 21Kd-ScFv can eliminate time Withrawal symptom-jump, but needed 21Kd-ScFv antibody amount does not wait, thus proof morphine tolerance and the formation that relies on also with brain in the increase of 21Kd albumen resultant quantity inseparable closely.
Table 1 is in morphine tolerance and rely on mouse, and 21Kd albumen soluble single-chain antibody (ScFv i.c.v.) back of injecting various dose in the tricorn is to the influence of the Withrawal symptom-number of skips of being brought out by Narlan (10mg/kg i.p.)
| Numbering | Control group | Numbering | Experimental group |
| No.5 | 0 | No.1 | 0 ScFv(i.C.v.)8μg×1 |
| No.3 | 1 | No.11 | 0 ScFv(i.C.v.)8μg×1 |
| No.9 | 15 | No.12 | 0 ScFv(i.C.v.)8μg×1 |
| No.6 | 36 | No.10 | 6→0?ScFv(i.C.v.)8μg×2 |
| No.7 | 89 | No.4 | 8→0?ScFv(i.C.v.)8μg×2 |
| No.8 | 90 | No.2 | 45→0?ScFv(i.C.v.)8μg×3 |
Embodiment 3, detection nmda receptor and the effect of NOS in anti-opioid 21Kd and active fragments antagonism morphine antinociceptic effect thereof
Studies show that, excitatory amino acid nmda receptor and nitric oxide synthetase system (NOS) play crucial effects in tolerance of adult mice morphine and dependence process, after with nmda receptor antagonist or no inhibitor mouse being carried out pre-treatment, the formation that can suppress the morphine tolerance and rely on, prevent appearance [the Adams ML of Withrawal symptom, Kalicki JM, Meyer ER, Cicero TJ (1993) Inhibition of the morphine withdrawal syndrome bynitric oxide synthase inhibitor, NG-Nitro-L-arginine methyl ester.Life Sci52:PL245-PL249; Cappendijk SL, Vries R, Dzoljic MR (1993) Inhibitory effectof nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawalsyndrome in morphine-dependent mice.Neurosci Lett 162:97-100; Herman BH, Vocci F, Bridge P (1995) The effect of NMDA receptor antagonists and nitricoxide synthase inhibitors on opioid tolerance and withdrawal.Neuropsychopharmacology 13:269-293; Vaupel DB, Kimes AS, London ED (1995b) Nitric oxide synthase inhibitors:preclinical studies of potential use fortreatment of opiate addiction.Neuropsychopharmacology 13:315-322; Trujillo K.A. (2000) A review of preclinical studies:Are NMDA receptorsinvolved in opiate-induced neural and behavioral plasticity? Psychopharmacology 151:121-141; Heinzen EL, Pollack G.M. (2004) Thedevelopment of morphine antinociceptive tolerance in nitric oxidesynthase-deficient mice.Biochem.Pharmacology vol 67 (4): 735-741].Use excitatory amino acid nmda receptor antagonist MK-801 (available from Sigma company respectively, 0.1mg/kg i.p.) in the injection preceding 15 minutes of morphine and with nitric oxide synthetase no inhibitor L-NAME (available from Sigma, 45mg/kg i.p.) in injecting morphine preceding 20 minutes, mouse is carried out pre-treatment, being blank (Blank) without pretreated mouse, use 21Kd (0.96nM) again, 21Kd-13 (22.7nM), 21Kd-14 (6.4nM) and 21Kd-21 (4.0nM) detect the influence to morphine (20mg/kg i.P.) antinociceptic effect, are contrast (Control) with physiological saline (Saline).(ordinate zou is a morphine antinociceptic effect area under a curve to the result, the cm of unit as shown in Figure 7
2X-coordinate projects are three kinds of contrasts, 21Kd, 21Kd-13,21Kd-14 and 21Kd-21), anti-opioid 21Kd and active fragments 21Kd-13 thereof, 21Kd-14,21Kd-21 peptide section is disengaged the antagonistic action of morphine antinociceptic effect, illustrates that anti-opioid 21Kd and bioactive peptide antagonism morphine antinociceptic effect thereof need the mediation of nmda receptor and NOS.Above-mentioned experimental result shows, handle with nmda receptor antagonist and no inhibitor, can suppress morphine tolerance and the formation that relies on and prevent the appearance of Withrawal symptom, may be that 21Kd albumen and active fragments thereof are disengaged the retarding effect of morphine antinociceptic effect in the brain, further specify in the brain 21Kd albumen and tolerate with morphine and rely on closely related.
The acquisition of embodiment 4, anti-opioid 21Kd antagonism peptide and active detection the thereof
One, the acquisition of CP-21Kd-13, CP-21Kd-14 and CP 21Kd-21 antagonism peptide
According to there being interactional principle between the protein molecule, reference (J.R.Heal et al (2002) Specific interactions between sense and complementary peptides:The Basis forthe proteomic code ChemBIOChem 3,136-151) design 21Kd-13,21Kd-14, the antagonism peptide of three small peptides of 21Kd-21, wherein, antagonism peptide called after CP-21Kd-13 with 21Kd-13, amino acid residue sequence with SEQ ID NO:9, form by 13 amino-acid residues, its encoding sequence has the nucleotide sequence of the SEQ ID NO:12 in the sequence table, by 49 based compositions; With the antagonism peptide called after CP-21Kd-14 of 21Kd-14, have the amino acid residue sequence of SEQ ID NO:10, to form by 14 amino-acid residues, its encoding sequence has the nucleotide sequence of the SEQ ID NO:13 in the sequence table, by 42 based compositions; With the antagonism peptide called after CP-21Kd-21 of 21Kd-21, have the amino acid residue sequence of SEQ ID NO:11, to form by 21 amino-acid residues, its encoding sequence has the nucleotide sequence of the SEQ ID NO:14 in the sequence table, by 63 based compositions;
Two, the activity of CP-21Kd-13, CP-21Kd-14 and CP-21Kd-21 antagonism peptide detects
1, detects CP-21Kd-13, CP-21Kd-14 and CP-21Kd-21 influence to the morphine antinociceptic effect
With with embodiment 1 step 2 in identical method detect CP-21Kd-21, CP-21Kd-14, CP-21Kd-13 peptide section is to the influence of morphine antinociceptic effect, method is: choose normal kunming mice, divide three groups (5 or 6 every group, n=5 or 6), inject CP-21Kd-13 (6mg/Kg i.v.) by the tail vein respectively, CP-21Kd-14 (5mg/Kg i.v.) and CP-21Kd-21 (5.6mg/Kg i.v.), detect influence again to morphine (20mg/kg i.P.) antinociceptic effect, with physiological saline is contrast (Saline 50 μ l i.V.), CP-21Kd-13 wherein, (X-coordinate is represented the time (min) behind the injection of morphia to the detected result of CP-21Kd-14 and CP-21Kd-21 injection group shown in Fig. 8 A-Fig. 8 C, ordinate zou is represented the variation (%) of vocalization threshold, n represents respectively to organize experiment mice quantity, i.p. represent intraperitoneal injection, i.v. represent the tail intravenous injection), compare with control group, injection CP-21Kd-21, CP-21Kd-14 or and CP-21Kd-13 after, the antinociceptic effect of morphine strengthens significantly, obviously these antagonism peptides play a part the anti-opioid inhibitor, have offset the effect of endogenous anti-opioid.In addition, because these antagonism peptide molecular weights are less than 2000 dalton, inject in the body and can enter central nervous system by the tail vein by hemato encephalic barrier, establish antagonism peptide CP-21Kd-21, CP-21Kd-14, CP-21Kd-13 and had the medicine that preparation strengthens morphine analgesia, the tolerance of reverse morphine and/or weakens or eliminate the Withrawal symptom effect, and the prospect that can carry out clinical application to described medicine.
2, CP-21Kd-21, CP-21Kd-14 and CP-21Kd-13 are to the influence of the morphine abstinence syndrome effect of being brought out by Narlan (Naloxone)
Choose healthy mice, every day three times, the morphine of subcutaneous injection ascending-dose, injected dose is that 10mg/kg is incremented to 80mg/kg, continues the tolerance of 12 days formation morphines and relies on mouse.Then morphine tolerance and dependence mouse are divided into control group (injecting normal saline) and experimental group.After the 13rd day last injection morphine 6-8 hour, the tail vein is injected antagonism peptide CP-21Kd-21 (15mg/kg), CP-21Kd-14 (15mg/kg) and CP-21Kd-13 (15.5mg/kg) respectively, (Saline 80 μ l i.V.) are contrast with physiological saline, 5 minutes pneumoretroperitoneum injection Naloxone (10mg/kg) observe the number of times that mouse is brought out Withrawal symptom-jump.The experimental result of CP-21Kd-21, CP-21Kd-14 and CP-21Kd-13 group is shown in table 2 and table 3, explanation is injected antagonism peptide CP-21Kd-21 (15mg/kg), CP-21Kd-14 (15mg/kg) and CP-21Kd-13 (15.5mg/kg) respectively by the tail vein, and the effect-jump of giving up that Naloxone (10mg/kg i.P.) brings out can be eliminated or obviously weaken.In addition, rank test is the result show: compare with control group-1, all there are significant difference (P=1-0.025=0.975) in CP-21Kd-21, CP-21Kd-14 and CP-21Kd-13 experimental group, the CP-21Kd-14 of escalated dose compares with contrast-3 with the CP-21Kd-13 group and also has extremely significant difference, therefore, antagonism peptide CP-21Kd-21, CP-21Kd-14 and CP-21Kd-13 all can effectively suppress or eliminate and give up effect.
Table 2 tail vein injection antagonism peptide CP-21Kd-21, CP-21Kd-14 and CP-21Kd-13 bring out morphine abstinence syndrome symptom--the influence of jump to Narlan (Naloxone 10mg/kg i.P.)
| No.1 | No.2 | No.3 | No.4 | No.5 | No.6 | No.7 | |
| Control group-1 ( |
8 | 18 | 25 | 35 | 38 | 51 | 71 |
| CP-21Kd-21***(15mg/kg?i.V.) | 0 | 1 | 5 | 11 | 18 | 18 | 25 |
| CP-21Kd-14***(15mg/kg?i.V.) | 0 | 0 | 3 | 3 | 7 | 10 | 21 |
| CP-21Kd-13***(15.5mg/kg?i.V.) | 0 | 0 | 0 | 1 | 6 | 9 | 56 |
* * rank test shows: compare with control group, difference is (P=1-0.025=0.975) extremely significantly.
Table 3 tail vein injection antagonism peptide CP-21Kd-14 (64mg/kg i.v.) and CP-21Kd-13 (48mg/kg i.v.) bring out morphine abstinence syndrome symptom--the influence of jump to Narlan (Naloxone 10mg/kg i.P.)
| No.1 | No.2 | No.3 | No.4 | No.5 | No.6 | No.7 | |
| Control group-3 ( |
66 | 83 | 91 | 97 | 114 | 147 | 554 |
| CP-21Kd-14***(64mg/kg?i.V.) | 0 | 1 | 4 | 23 | 39 | 57 | 62 |
| CP-21Kd-13***(48mg/kg?i.V.) | 0 | 0 | 3 | 8 | 23 | 36 | / |
* * rank test shows: compare with control group, difference is (P=1-0.025=0.975) extremely significantly.
Sequence table
＜110〉Peking University
＜120〉a kind of active fragments of anti-opioid
<130>CCGNAZ102104
<160>14
<210>1
<211>186
<212>PRT
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>1
Pro?Val?Asp?Leu?Ser?Lys?Trp?Ser?Gly?Pro?Leu?Ser?Leu?Gln?Glu?Val
1 5 10 15
Asp?Glu?Arg?Pro?Gln?His?Pro?Leu?Gln?Val?Lys?Tyr?Gly?Gly?Ala?Glu
20 25 30
Val?Asp?Glu?Leu?Gly?Lys?Val?Leu?Thr?Pro?Thr?Gln?Val?Lys?Asn?Arg
35 40 45
Pro?Thr?Ser?Ile?Thr?Trp?Asp?Gly?Leu?Asp?Pro?Gly?Lys?Leu?Tyr?Thr
50 55 60
Leu?Val?Leu?Thr?Asp?Pro?Asp?Ala?Pro?Ser?Arg?Lys?Asp?Pro?Lys?Tyr
65 70 75 80
Arg?Glu?Trp?His?His?Phe?Leu?Val?Val?Asn?Met?Lys?Gly?Asn?Asn?Ile
85 90 95
Ser?Ser?Gly?Thr?Val?Leu?Ser?Asp?Tyr?Val?Gly?Ser?Gly?Pro?Pro?Lys
100 105 110
Gly?Thr?Gly?Leu?His?Arg?Tyr?Val?Trp?Leu?Val?Tyr?Glu?Gln?Glu?Gly
115 120 125
Pro?Leu?Lys?Cys?Asp?Glu?Pro?Ile?Leu?Ser?Asn?Arg?Ser?Gly?Asp?His
130 135 140
Arg?Gly?Lys?Phe?Lys?Val?Ala?Ser?Phe?Arg?Lys?Lys?Tyr?Glu?Leu?Gly
145 150 155 160
Ala?Pro?Val?Ala?Gly?Thr?Cys?Tyr?Gln?Ala?Glu?Trp?Asp?Asp?Tyr?Val
165 170 175
Pro?Lys?Leu?Tyr?Glu?Gln?Leu?Ser?Gly?Lys
180 185
<210>2
<211>558
<212>DNA
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>2
ccggtggacc?ttagcaagtg?gtccgggcct?ctgagcctgc?aggaagtgga?tgagcggccg 60
cagcacccgc?tgcaggtcaa?atacggcggg?gcggaggtcg?acgaactggg?caaagtgctg 120
acacccaccc?aggttaaaaa?ccggcccacc?agcattacat?gggatggcct?tgatccaggt 180
aaattgtaca?ccttggtctt?gacagatccg?gatgctccca?gcaggaagga?ccccaaatac 240
agggaatggc?accatttcct?ggtggtcaac?atgaagggca?acaacatcag?cagtggcacg 300
gttctctccg?attatgtggg?ctctgggcct?cccaagggca?caggcctgcg?ccgctatgtc 360
tggctggttt?acgagcagga?aggaccactg?aagtgtgatg?agcccattct?cagcaaccga 420
tctggagacc?accgtggcaa?attcaaggtg?gcctctttcc?gcaaaaagta?cgagcttggg 480
gccccagtgg?ccggcacgtg?ttaccaggcc?gaatgggatg?attatgtgcc?caagctctac 540
gagcagctgt?ctgggaag 558
<210>3
<211>13
<212>PRT
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>3
Tyr?Arg?Glu?Trp?His?His?Phe?Leu?Val?Val?Asn?Met?Lys
1 5 10
<210>4
<211>14
<212>PRT
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>4
Leu?Tyr?Thr?Leu?Val?Leu?Thr?Asp?Pro?Asp?Ala?Pro?Ser?Arg
1 5 10
<210>5
<211>21
<212>PRT
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>5
Trp?Ser?Gly?Pro?Leu?Ser?Leu?Gln?Glu?Val?Asp?Glu?Arg?Pro?Gln?His
1 5 10 15
Pro?Leu?Gln?Val?Lys
20
<210>6
<211>39
<212>DNA
＜213〉wild boar be born in the year of pig (Sus scrofa domes tica Brisson)
<400>6
tacagagagt?ggcaccactt?cctggtggtg?aacatgaag 39
<210>7
<211>42
<212>DNA
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>7
ctgtacaccc?tggtgctgac?cgaccccgac?gcccccagca?ga 42
<210>8
<211>63
<212>DNA
＜213〉wild boar be born in the year of pig (Sus scrofa domestica Brisson)
<400>8
tggagcggcc?ccctgagcct?gcaggaggtg?gacgagagac?cccagcaccc?cctgcaggtg 60
aag 63
<210>9
<211>13
<212>PRT
＜213〉artificial sequence
<220>
<223>
<400>9
Val?Ser?Leu?Pro?Val?Val?Glu?Gln?His?His?Val?His?Leu
1 5 10
<210>10
<211>14
<212>PRT
＜213〉artificial sequence
<220>
<223>
<400>10
Gln?Val?Gly?Gln?His?Gln?Gly?Val?Gly?Val?Gly?Gly?Ala?Ser
1 5 10
<210>11
<211>21
<212>PRT
＜213〉artificial sequence
<220>
<223>
<400>11
Pro?Ala?Ala?Gly?Gln?Ala?Gln?Leu?Leu?His?Val?Leu?Ser?Gly?Leu?Val
1 5 10 15
Gly?Gln?Leu?His?Leu
20
<210>12
<211>39
<212>DNA
＜213〉artificial sequence
<220>
<223>
<400>12
gtctctctcc?cagtcgtcga?acagcatcat?gtccatctc 39
<210>13
<211>42
<212>DNA
＜213〉artificial sequence
<220>
<223>
<400>13
caggtcgggc?agcatcaggg?ggtcggggtc?gggggggctt?ct 42
<210>14
<211>63
<212>DNA
＜213〉artificial sequence
<220>
<223>
<400>14
ccagctgctg?ggcaggctca?gctcctccat?gtcctctctg?ggctcgtcgg?gcagctccat 60
ctc 63
Claims (6)
1. the active fragments of an anti-opioid, its amino acid residue sequence is shown in the SEQ ID NO:3 in the sequence table.
2. the gene of coding claim 1 described anti-opioid active fragments.
3. gene according to claim 2 is characterized in that: the nucleotide sequence of described gene is shown in the dna sequence dna of SEQ ID NO:6 in the sequence table.
4. contain claim 2 or 3 described expression carrier.
5. the transgenic cell line that contains claim 2 or 3 described genes.
6. the host bacterium that contains claim 2 or 3 described genes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101226191A CN101817877B (en) | 2007-06-28 | 2007-06-28 | Anti-opioid peptide active fragment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101226191A CN101817877B (en) | 2007-06-28 | 2007-06-28 | Anti-opioid peptide active fragment |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101181042A Division CN101113172B (en) | 2007-06-28 | 2007-06-28 | Anti-opium peptide and antagonistic peptide and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101817877A CN101817877A (en) | 2010-09-01 |
| CN101817877B true CN101817877B (en) | 2011-09-14 |
Family
ID=42653167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101226191A Expired - Fee Related CN101817877B (en) | 2007-06-28 | 2007-06-28 | Anti-opioid peptide active fragment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101817877B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022557A1 (en) * | 1994-02-21 | 1995-08-24 | Astra Aktiebolag | Novel opioid peptides for the treatment of pain and use thereof |
| CN1626245A (en) * | 2003-09-16 | 2005-06-15 | 薛毅珑 | New application of chromaffin cell of adrenal medulla or opium peptide energy cell |
-
2007
- 2007-06-28 CN CN2010101226191A patent/CN101817877B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995022557A1 (en) * | 1994-02-21 | 1995-08-24 | Astra Aktiebolag | Novel opioid peptides for the treatment of pain and use thereof |
| CN1626245A (en) * | 2003-09-16 | 2005-06-15 | 薛毅珑 | New application of chromaffin cell of adrenal medulla or opium peptide energy cell |
Non-Patent Citations (2)
| Title |
|---|
| 杨树长等.猪脑抗吗啡镇痛肽的分离纯化及其抗血清对吗啡耐受影响的初步研究.《生物化学杂志》.1997,第13卷(第3期),322-326. * |
| 陈淑娟等.抗吗啡活性肽的分离纯化及一级结构测定.《生物化学杂志》.1996,第12卷(第2期),211-214. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101817877A (en) | 2010-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jameson et al. | A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis | |
| Li et al. | Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor | |
| CN102875653B (en) | Alpha-conotoxin peptide, and medical composition, preparation method and purpose thereof | |
| JP2020501584A (en) | Novel variants of α-conotoxin peptide TxID, pharmaceutical compositions and uses thereof | |
| KR20240109262A (en) | Uses of polypeptides, complexes and polypeptides in resistance to addiction and its relapse | |
| CN105985410B (en) | Cone shell peptide, its pharmaceutical composition and purposes | |
| CN102190708B (en) | Barrel-shaped alpha conantokin Bt1.3 and application thereof | |
| CN102718857A (en) | Denatured protein powder and brain protein hydrolyzate prepared from same | |
| WO2020057012A1 (en) | Application of cobra neurotoxin molecules having high affinity with nicotinic acetylcholine receptor and fast-onset in pain alleviation | |
| CN103113456B (en) | Stiff silkworm polypeptide with antiplatelet aggregation activity as well as preparation method and application of stiff silkworm polypeptide | |
| CN101648000B (en) | Application of cobrotoxin in preparing medicine for treating arthritis | |
| CN103275187A (en) | Analgesic peptide FI as well as genes and application thereof | |
| CN102351951A (en) | Purification method, extract and preparation of cobra venom neurotoxin | |
| CN101817877B (en) | Anti-opioid peptide active fragment | |
| CN101805396B (en) | Antagonistic peptide of anti-opioid peptide and application of antagonistic peptide | |
| US10428115B2 (en) | Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain | |
| CN101805402B (en) | Anti-opioid peptide active fragment | |
| CN101798338B (en) | Application of anti-opioid peptide antagonist peptide | |
| CN101113172B (en) | Anti-opium peptide and antagonistic peptide and its application | |
| CN104262461A (en) | Alpha-conotoxin TxIC, medicinal composition thereof, preparation method thereof and application | |
| CN101805394A (en) | Anti-opioid peptide active fragment | |
| CN101323641B (en) | Anti-opioid peptide, antagonistic peptide thereof and use thereof | |
| US7294697B2 (en) | Short chain neurotoxin from sea snake-Lapemis hardwickii and genes encoding the neurotoxin | |
| CN108359001B (en) | Conotoxin mutant polypeptide lv1c-AA and application and preparation method thereof | |
| CN102127152B (en) | Antagonistic peptide of anti-opioid peptide and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110914 Termination date: 20140628 |
|
| EXPY | Termination of patent right or utility model |